Chromosomal Abnormalities & IVF: How PGT/PGD Selects Healthy Embryos

Key Takeaways: Chromosomal abnormalities are the leading genetic cause of recurrent miscarriage and birth defects — but they do not have to prevent you from having a healthy child. Third-generation IVF technology, specifically Preimplantation Genetic Testing (PGT), enables precise chromosomal screening of embryos before transfer. By selecting only genetically normal embryos for implantation, PGT significantly raises success rates, reduces miscarriage risk, and has helped many families at high genetic risk achieve their dream of a healthy baby.

Quick Reference Guide

Test Type	Full Name	Indicated For	What It Detects
PGT-A	Preimplantation Genetic Testing for Aneuploidies	Advanced maternal age, recurrent miscarriage, repeated IVF failure	Chromosomal number abnormalities (e.g., Down syndrome)
PGT-M	Preimplantation Genetic Testing for Monogenic Disorders	Single-gene disorder carriers	Specific gene mutations (e.g., thalassemia, SMA)
PGT-SR	Preimplantation Genetic Testing for Structural Rearrangements	Balanced translocation/inversion carriers	Chromosomal structural rearrangements
Detection Technology	NGS Next-Generation Sequencing (current standard)	—	Whole-genome level
Reported Accuracy	>98% (for aneuploidies)	—	Single biopsy
Approximate Cost	USD 1,500–3,000 per batch (varies by clinic)	—	—

---

1. Common Types of Chromosomal Abnormalities and Their Impact on Fertility

Normal human cells contain 46 chromosomes (23 pairs). Any deviation in the number or structure of chromosomes can have serious consequences for fertility and the health of offspring.

Numerical Chromosomal Abnormalities (Aneuploidy)

This is the most common type of chromosomal abnormality, referring to any situation where the chromosome count is not a multiple of the normal 46.

Common types:

• Trisomy: Three copies of a chromosome instead of the normal two. The most prevalent are Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
• Monosomy: Only one copy of a chromosome. Turner syndrome (45,X) is the most common monosomy compatible with live birth.
• Polyploidy: An entire extra set of chromosomes, such as triploidy (69 chromosomes), which is essentially incompatible with survival.

Impact on fertility:

• The vast majority of aneuploid embryos are naturally eliminated before implantation or during early pregnancy — nature's own quality control mechanism;
• Some may implant but result in biochemical pregnancy or early miscarriage;
• A very small fraction survive to birth, presenting with varying degrees of intellectual disability and physical abnormalities.

Age-related risk: The rate of meiotic division errors in female oocytes increases significantly with age. After 35, the proportion of aneuploid embryos retrieved per cycle rises sharply:

• Age 35: approximately 30%–40% of embryos may be chromosomally abnormal;
• Age 40: rises to approximately 60%–70%;
• Age 43 and above: can exceed 75%–85%.

This is the core genetic explanation for why older women experience higher rates of repeated IVF failures and miscarriages.

Structural Chromosomal Abnormalities

Structural abnormalities occur when chromosomal segments are rearranged. Common types include:

Balanced Translocation:

• Segments are exchanged between two non-homologous chromosomes, with no net gain or loss of genetic material ("balanced") — carriers typically appear phenotypically normal;
• However, during gametogenesis, a large proportion of gametes carry "unbalanced" chromosomal rearrangements;
• Fertilization with an unbalanced gamete almost always results in miscarriage or a child with birth defects.

Robertsonian Translocation:

• The long arms of two acrocentric chromosomes (13, 14, 15, 21, or 22) fuse;
• The most common variant, 14/21 translocation, allows carriers to reproduce normally, but approximately one-third of offspring will have Down syndrome.

Inversion:

• A chromosomal segment is inverted and reinserted; classified as pericentric (involving the centromere) or paracentric;
• Carriers are typically phenotypically normal but may produce abnormal gametes during meiosis.

Microdeletions/Microduplications:

• Small chromosomal segments are deleted or duplicated, undetectable by conventional karyotyping (light microscopy);
• Require high-resolution chromosomal microarray (CMA) or NGS technology for detection;
• Associated with numerous genetic syndromes (e.g., 22q11 deletion causing DiGeorge syndrome).

Single-Gene (Monogenic) Disorders

Single-gene disorders result from mutations in specific genes; standard chromosomal karyotyping cannot detect them — targeted genetic testing is required.

• Autosomal recessive: Both parents are carriers; offspring have a 1-in-4 chance of being affected (e.g., thalassemia, cystic fibrosis, spinal muscular atrophy/SMA);
• Autosomal dominant: A mutation in one copy of the gene is sufficient to cause disease; offspring have a 1-in-2 chance of inheriting the condition (e.g., Huntington's disease);
• X-linked disorders: Gene is located on the X chromosome (e.g., hemophilia, Duchenne muscular dystrophy/DMD).

---

2. A Comprehensive Guide to PGT Technology in Third-Generation IVF

Preimplantation Genetic Testing (PGT) is the cornerstone of third-generation IVF. Once embryos have developed to the blastocyst stage (day 5–6 post-fertilization), a small number of trophectoderm cells are biopsied and subjected to genetic analysis. Only embryos that pass this genetic screen are selected for transfer.

PGT-A: Aneuploidy Screening

Full name: Preimplantation Genetic Testing for Aneuploidies

What it tests: Screens all 23 chromosome pairs for copy number, identifying euploid (chromosomally normal) embryos.

Indicated for:

• Advanced maternal age (AMA, age ≥ 35);
• Recurrent pregnancy loss (≥2 miscarriages);
• Repeated IVF failure (≥2 failed transfers of good-quality embryos);
• Prior pregnancy with chromosomal abnormality (e.g., Down syndrome);
• Severe male factor infertility (high rate of sperm chromosomal abnormalities).

Clinical value:

• Transferring only euploid embryos yields clinical pregnancy rates of approximately 60%–70% per transfer (varies by age and ovarian function);
• Miscarriage rate drops from approximately 20%–25% (standard IVF) to approximately 5%–10%;
• Reduces unnecessary transfer attempts, minimizing the physical and emotional burden of failed cycles and pregnancy loss.

PGT-M: Monogenic Disorder Testing

Full name: Preimplantation Genetic Testing for Monogenic Disorders

What it tests: Using targeted gene sequencing or linkage analysis, screens embryos for a specific known familial gene mutation.

Indicated for:

• Both partners are carriers of an autosomal recessive disorder (e.g., thalassemia, SMA);
• One partner is affected by an autosomal dominant disorder (e.g., Huntington's disease);
• Female partner is a carrier of an X-linked disorder (e.g., hemophilia);
• Familial hereditary cancer syndromes (e.g., BRCA1/2 mutations).

Special requirement: Requires advance preparation — typically family genetic analysis and probe design should be completed 2–3 months before the stimulation cycle begins.

PGT-SR: Structural Rearrangement Testing

Full name: Preimplantation Genetic Testing for Structural Rearrangements

What it tests: Specifically designed for carriers of chromosomal translocations, inversions, or other structural rearrangements; screens embryos for unbalanced chromosomal rearrangements.

Indicated for:

• Balanced translocation carriers;
• Robertsonian translocation carriers;
• Chromosomal inversion carriers;
• History of multiple miscarriages or stillbirths due to chromosomal structural abnormalities.

Clinical value: By selecting chromosomally normal or balanced-carrier embryos, PGT-SR dramatically reduces miscarriage rates and improves live birth rates. For balanced translocation carriers, PGT-SR can improve per-transfer live birth rates from approximately 10%–20% (natural conception) to approximately 45%–60%.

---

3. The Real Advantages — and Real Limitations — of PGT

Understanding both what PGT can and cannot do is essential for making informed decisions.

Key Advantages of PGT

1. Substantially reduced miscarriage rates PGT-A selection of euploid embryos reduces post-transfer miscarriage rates from approximately 20%–25% (standard IVF) to approximately 5%–10% — a transformational benefit for patients with recurrent pregnancy loss.

2. Higher per-transfer success rates For older patients or those with chromosomal issues, each euploid embryo transfer achieves clinical pregnancy rates of approximately 60%–70%, significantly higher than unscreened embryo transfer (approximately 30%–50%, depending on age).

3. Fewer unnecessary transfer attempts Pre-transfer screening eliminates known chromosomally abnormal embryos, reducing futile cycles and the cumulative physical and psychological toll they take.

4. Lower risk of chromosomal birth defects Common chromosomal number abnormalities such as Down syndrome can be reduced to extremely low birth rates (approximately 0.1% or less).

5. Sex selection for medical indications For X-linked disorders, embryo sex can be simultaneously confirmed, enabling selection of unaffected embryos.

Limitations of PGT

1. Cannot guarantee 100% healthy outcomes PGT primarily screens chromosomal-level issues (PGT-A/SR) or specific known gene mutations (PGT-M). It cannot capture all genetic variants, new mutations, or multifactorial disorders. A normal PGT result does not equal a completely normal embryo — routine prenatal screening during pregnancy (NT ultrasound, NIPT/cell-free DNA, amniocentesis if indicated) remains necessary.

2. Inherent technical limitations

• The clinical management of mosaic embryos (partially normal, partially abnormal) remains a subject of ongoing debate;
• Trophectoderm biopsy cells are not a perfect representation of the inner cell mass (which gives rise to the fetus);
• A small but non-zero rate of diagnostic error exists (approximately 1%–2% false positives or false negatives).

3. Reduced number of transferable embryos After PGT-A screening, the number of euploid embryos available for transfer may be significantly reduced — especially for older patients:

• Under 35: approximately 60%–70% of blastocysts are euploid;
• Age 40: only approximately 30%–40% of blastocysts are euploid;
• Age 43 and above: may fall to 15%–25%.

This means some patients may need multiple retrieval cycles to accumulate enough transferable embryos.

4. Additional cost and time PGT requires additional laboratory fees (typically USD 1,500–3,000 per batch) and a waiting period for results (approximately 1–2 weeks). It is therefore typically performed in conjunction with frozen embryo transfer (FET) rather than fresh transfer.

5. Extremely small risk of embryo damage Trophectoderm biopsy at the blastocyst stage is a well-established procedure, but a theoretically minimal risk of embryo damage (<1%) exists. In experienced laboratories, this risk is minimized to the greatest possible extent.

---

4. AddBaby's PGT Program and Clinical Cases

AddBaby Medical Center operates one of the most advanced embryo genetics laboratories in the field, using the latest-generation NGS technology platform to provide fully integrated services — from genetic counseling through PGT testing through embryo transfer — for every patient.

Technology Platform: Next-Generation Sequencing (NGS)

AddBaby's NGS platform offers significant advantages over traditional fluorescence in situ hybridization (FISH):

• Whole-genome coverage: Screens all 23 chromosome pairs in a single test, rather than only specific chromosomes;
• Higher resolution: Detects microdeletions/microduplications (>5–10 Mb) invisible to FISH;
• Integrated chromosomal microarray (CMA): For select patients, further enhances detection precision;
• Mosaic grading reports: Provides mosaicism percentage (0%–100%), enabling more nuanced and precise transfer decisions.

Integrated Genetic Counseling

Before initiating PGT, AddBaby provides comprehensive genetic counseling:

• Karyotyping for both partners: Identifies structural abnormality types and determines PGT-SR applicability;
• Family history assessment: Identifies single-gene disorder risks and determines whether PGT-M is warranted;
• Individualized test design: Detection strategy is customized based on defect type, severity, and family history;
• Results interpretation support: Genetic counselors explain reports in full and help patients understand the clinical significance of findings.

Transparent Pricing

AddBaby is committed to full fee transparency:

• PGT-A (per batch, up to 5 blastocysts): approximately USD 1,500–2,000;
• PGT-SR (per batch): approximately USD 2,000–2,500;
• PGT-M (including probe design): approximately USD 2,500–3,500;
• Report turnaround: 7–10 business days after biopsy;
• All fees are confirmed in writing before testing is initiated; no hidden charges.

Real-World Case Examples

Case 1: Balanced Translocation Carrier A 35-year-old patient whose husband carried a 14/21 chromosomal balanced translocation. History of 3 spontaneous miscarriages and 1 failed IVF cycle (without PGT). PGT-SR screening of 3 blastocysts identified: 1 chromosomally normal, 1 balanced carrier (clinically acceptable), and 1 unbalanced (not transferred). Transfer of the balanced-carrier embryo resulted in a successful live birth; the newborn's karyotype was confirmed normal.

Case 2: Advanced-Age Patient with Repeated Failures A 42-year-old patient with 3 failed IVF transfers (6 total embryos transferred without PGT). In a single stimulation cycle, 8 eggs were retrieved, forming 5 blastocysts. PGT-A results: 2 euploid, 1 mosaic (low-level, approximately 20% abnormal cells), 2 aneuploid (not transferred). Transfer of the euploid embryo resulted in successful implantation and live birth.

---

Frequently Asked Questions (FAQ)

Q1: I carry a balanced chromosome translocation. Can I still have a healthy child?

A: Yes — with the assistance of PGT-SR. Balanced translocation carriers have the correct total amount of chromosomal material, so they are typically phenotypically normal themselves. However, during meiosis (gamete formation), the rearranged chromosomes can segregate into four types of gametes: normal (25%), balanced-carrier (25%), and two unbalanced forms (25% each). Fertilization with an unbalanced gamete almost invariably results in miscarriage or a child with birth defects. PGT-SR screens embryos before transfer, selecting only normal or balanced-carrier embryos — improving per-transfer live birth rates from approximately 10%–20% (natural conception) to approximately 45%–60%.

Q2: Is PGT testing 100% accurate? Do I still need prenatal diagnosis during pregnancy?

A: PGT accuracy is very high (>98%), but it is not 100%. Reasons include: the representational limitations of trophectoderm biopsy cells (particularly in mosaic embryos), a very small technical error rate, and the fact that PGT cannot cover every possible genetic disease (such as de novo mutations and polygenic disorders). Therefore, it is strongly recommended that all patients who achieve pregnancy after PGT continue with standard prenatal screening: first-trimester NT ultrasound (11–13 weeks), cell-free fetal DNA testing (NIPT, typically 10–14 weeks), and amniocentesis if indicated. PGT is a "screening" tool; prenatal diagnosis provides "confirmation." The two are complementary — neither replaces the other.

Q3: Do I still need NIPT (non-invasive prenatal testing) after PGT-A?

A: Generally yes, it is advisable. Even if PGT-A has confirmed that a euploid embryo was transferred, NIPT during pregnancy still provides important value:

• Provides a second-level confirmation of fetal chromosomal status, reducing the impact of any laboratory error;
• Detects scenarios that PGT may have missed (e.g., low-level mosaicism, de novo mutations);
• Screens for sex chromosome abnormalities (sex chromosome reporting from some PGT-A platforms benefits from NIPT confirmation);
• NIPT is part of standard prenatal care workflows at most hospitals in China and many international centers.

Q4: Does PGT biopsy reduce embryo viability? Can it harm the embryo?

A: Trophectoderm biopsy performed at the blastocyst stage has minimal impact on the embryo when carried out in an experienced laboratory. A substantial body of clinical data confirms that PGT-A does not adversely affect subsequent embryo developmental potential or pregnancy outcomes. The critical points are:

• Biopsy must be performed at the blastocyst stage (day 5–6 post-fertilization), not earlier-stage cleavage biopsy;
• Trophectoderm cells (destined to become the placenta) are biopsied, not inner cell mass cells (which become the fetus);
• The procedure must be performed by certified embryologists — all AddBaby laboratory personnel hold relevant professional certifications.

Q5: What if all of my embryos have abnormal PGT results?

A: This is a real possibility that must be faced — particularly for older patients. Options include:

1. Additional retrieval cycles: Proceed to another stimulation cycle to generate more blastocysts for screening and accumulate usable embryos;
2. Evaluate mosaic embryos: Low-level mosaic embryos (<30% abnormal cells) can sometimes be considered for transfer after thorough informed consent — some do develop normally;
3. Donor eggs: If your own egg quality is consistently too poor to yield normal embryos, donor eggs represent an effective pathway to a healthy pregnancy, typically with higher success rates than autologous IVF;
4. Embryo donation: Appropriate when both partners have significant genetic challenges.

We recommend a thorough discussion with your reproductive specialist and genetic counselor to evaluate all options and make the decision best suited to your specific situation.

---

Conclusion: PGT Makes Healthy Babies a Reality for Families at High Genetic Risk

Chromosomal abnormalities were once the hidden reason behind repeated miscarriages and years of unexplained IVF failures for many families. The advent of PGT technology in third-generation IVF fundamentally changed that reality — enabling us to examine an embryo's genetic status before it is ever implanted. By prioritizing the transfer of chromosomally normal embryos, PGT has dramatically improved live birth rates and reduced the devastating cycle of miscarriage that so many couples endure.

Of course, PGT is not a panacea. Its value is maximized when integrated with expert genetic counseling, an individualized IVF protocol, and comprehensive prenatal monitoring throughout pregnancy.

AddBaby Medical Center maintains a complete PGT testing platform and dedicated genetic counseling team, offering customized solutions for patients facing chromosomal translocations, monogenic disorders, recurrent pregnancy loss, and all forms of high genetic-risk infertility. If chromosomal abnormalities are complicating your path to parenthood, we invite you to schedule a genetic counseling consultation and take the first step toward your third-generation IVF journey.

Related Reading:

• PGD/PGT-A Embryo Genetic Testing Services
• Recurrent Miscarriage: Causes and Solutions
• Complete IVF Treatment Process Overview

---

This article has been reviewed by the AddBaby Medical Center clinical team. Last updated: February 2026